R&D Novel study designs for rare diseases Developing treatments for rare diseases poses many unique challenges that cannot be addressed by traditional study designs.
R&D Trajectory-based diagnostics enable early intervention in pr... Diagnostic testing in modern medicine remains largely episodic and threshold-based.
R&D Q2 clinical trials round-up: April to June 2025 The second quarter of 2025 has seen a surge of clinical trial activity across the pharmaceutical and biotech landscape.
R&D Changing Faces – Pharma and biotech hires for June 2025 Read on for some of the key appointments of last month. Bristol Myers Squibb adds two executive leaders.
R&D Immune mediation, B-cell depletion, and female leadership – ... In a new pharmaphorum podcast, Aoife Brennan, CEO of Climb Bio, discusses the treatment of immune-mediated diseases.
R&D Bridging science and care: Advancing biomedical innovation As public funding becomes more uncertain, lab and clinical services professionals are increasingly being called on to help.
News Alzheimer's biotech Korsana to go public via reverse merger By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer's.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
